Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.56 |
| ▸ | NAMPT | P43490 | 4/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8169311 | 0.86 | LMNA (0.66) | POLBNAMPTLMNAGAA | |
| SCHEMBL12010986 | 0.80 | RAB9A (0.80) | POLBTAAR1SGMS2LRRK2NAMPT | |
| SCHEMBL17551873 | 0.79 | SGMS2 (0.89) | SGMS2LRRK2 | |
| SCHEMBL6260237 | 0.78 | PTGER1 (0.62) | — | |
| SCHEMBL19133749 | 0.78 | SGMS2 (1.00) | SGMS2LRRK2 | |
| SCHEMBL30322841 | 0.78 | SGMS2 (1.00) | SGMS2LRRK2 | |
| SCHEMBL8162286 | 0.77 | SPHK2 (0.57) | SGMS2RAB9ANPC1LMNA | |
| SCHEMBL31261596 | 0.77 | SGMS2 (0.76) | POLBTAAR1SGMS2LRRK2RAB9A | |
| SCHEMBL8174051 | 0.76 | NPC1 (0.53) | RAB9ANPC1LMNA | |
| SCHEMBL6258686 | 0.76 | PTGER1 (0.50) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0752421-B1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | POLB 2940/4885TAAR1 550/4885SGMS2 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.